You can buy or sell Cytokinetics and other stocks, options, and ETFs commission-free!
Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA. The listed name for CYTK is Cytokinetics, Incorporated Common Stock.
Robert I. Blum
South San Francisco, California
52 Week High
52 Week Low
— per share
Expected Mar 4, After Hours